Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Conflict of interest br There is no interest

    2020-08-03


    Conflict of interest
    There is no interest conflict.
    Acknowledgements
    This work was supported by Mackay Memorial Hospital grants MMH-107-68.
    References
    [2] Grabowski J, Sehouli J. Current management of ovarian cancer. Minerva Med 2015;106:151e6. [3] Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportu-nities for translation. Nat Rev Cancer 2009;9:415e28. [4] Badgwell D, Bast Jr RC. Early detection of ovarian cancer. Dis Markers 2007;23: 397e410. [5] Kobayashi E, Ueda Y, Matsuzaki S, Yokoyama T, Kimura T, Yoshino K, et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Prev Biomark 2012;21:1902e12. [6] Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase in-hibitors. Nat Rev Cancer 2009;9:28e39. [7] Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlo-tinib (Tarceva®) and gefitinib (Iressa®). Oncologist 2005;10:579e89.
    [8] Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko C-w, Sridhara R, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008;13:1114e9.
    [9] Birchmeier C, Birchmeier W, Gherardi E, Woude GFV. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915e25. [10] Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670e9.
    [11] Ma P, Tretiakova M, Nallasura V, Jagadeeswaran R, Husain A, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 2007;97: 368e77.
    [12] Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41e59. [13] Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7: 504e16.
    [14] Kwon Y, Smith BD, Zhou Y, Kaufman MD, Godwin AK. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer Geneticin, G-418 Sulfate is influenced by the ovarian tissue microenvironment. Oncogene 2015;34: 144e53.
    [18] Dai Y, Siemann DW. BMS-777607, a small-molecule Met kinase inhibitor, suppresses hepatocyte growth factorestimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Therapeut 2010;9:1554e61.
    [20] Sharma S, Zeng J-Y, Zhuang C-M, Zhou Y-Q, Yao H-P, Hu X, et al. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Therapeut 2013;12:725e36.
    [21] Sourbier C. Ovarian cancer: emerging molecular-targeted therapies. Biologics 2012;6:147e54. [22] Toss A, Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res 2015;17:60. [23] Sulpice E, Ding S, Muscatelli-Groux B, Berge M, Han ZC, Plouet J, et al. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol Cell 2009;101:525e39. [24] Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: cur-rent clinical perspectives and future potential. Clin Cancer Res 2013;19: 961e8.
    [30] Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68e73. Accepted Manuscript
    Antitumor effects of seleno-β-lactoglobulin on human breast cancer MCF-7 and MDA-MB-231 cells in vitro
    Xiaomeng Xu, Yingying Feng, Xiaoyu Chen, Qinjian Wang, Ting Meng, Anjun Liu
    This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
    ACCEPTED MANUSCRIPT
    Antitumor effects of seleno-β-lactoglobulin on human breast cancer MCF-7 and
    Xiaomeng Xua,b,Yingying Fenga, Xiaoyu Chena, Qinjian Geneticin, G-418 Sulfate Wanga,Ting Menga, Anjun Liua,*
    a Key Laboratory of Food Nutrition and Safety, Ministry of Education, College of Food Engineering and Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, PR China